Myeloma Trial, Recruiting (NCT06630104)

Myeloma Trial, Recruiting NCT06630104 Sponsor: Mayo Clinic Condition: Myeloma

Printed from Voxsanity (voxsanity.com.au) — NCT06630104 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Myeloma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You must be 18 years old or older
You must have a confirmed diagnosis of multiple myeloma (a type of blood cancer) or a type of blood/immune system cancer that has a specific marker called CD19+, diagnosed using standard medical tests
You must be willing and able to sign a consent form agreeing to take part
You must be willing to provide bone marrow samples (taken during a standard medical procedure) for research purposes
You must be willing to provide hair follicle samples for research purposes
You must be willing to come back to the enrolling hospital or clinic for follow-up appointments during the active part of the study
You must be willing to provide saliva and cheek swab samples for research purposes

Who may not be able to join:

You may not be able to join if you are not considered a suitable candidate for a type of treatment called CAR-T therapy (confirm with trial site)
You may not be able to join if you were diagnosed with a type of bone marrow or blood cell cancer called a myeloid neoplasm before receiving CAR-T therapy

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Mithun V. Shah, MD, Mayo Clinic in Rochester

Phone: 855-776-0015

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06630104

Sponsor: Mayo Clinic

Phase: Not Applicable

Status: Recruiting

Condition: Myeloma

Trial contact: 855-776-0015

More information: https://clinicaltrials.gov/study/NCT06630104

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You must be 18 years old or older
You must have a confirmed diagnosis of multiple myeloma (a type of blood cancer) or a type of blood/immune system cancer that has a specific marker called CD19+, diagnosed using standard medical tests
You must be willing and able to sign a consent form agreeing to take part
You must be willing to provide bone marrow samples (taken during a standard medical procedure) for research purposes
You must be willing to provide hair follicle samples for research purposes
You must be willing to come back to the enrolling hospital or clinic for follow-up appointments during the active part of the study
You must be willing to provide saliva and cheek swab samples for research purposes

Who may not be able to join:

You may not be able to join if you are not considered a suitable candidate for a type of treatment called CAR-T therapy (confirm with trial site)
You may not be able to join if you were diagnosed with a type of bone marrow or blood cell cancer called a myeloid neoplasm before receiving CAR-T therapy

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Mayo Clinic

Registry

ClinicalTrials.gov

Start date

22 November 2024

Est. completion

16 December 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Pathogenic and likely pathogenic germline and somatic variants associated with increased risk; Unexplained cytopenia

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov